Fexmid

Quick links to important sections

Fexmid

Method of action: Miorelaxant, Muscle Relaxant

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fexmid

Property Description
Active ingredient Cyclobenzaprine Hydrochloride
Form Tablet (Immediate/Extended-Release)
Pharmacological class Skeletal Muscle Relaxant
General therapeutic purpose Relieves acute muscle spasms
Origin Synthetic (Tricyclic Amine Derivative)

What Type of Medicine is Fexmid?

Fexmid is a prescription-only pharmaceutical preparation whose active ingredient is Cyclobenzaprine Hydrochloride. It is clinically recognized as a centrally acting skeletal muscle relaxant. This classification indicates that the drug's therapeutic action is mediated by the central nervous system (CNS), primarily at the brain stem level, rather than through direct influence on the muscle tissue itself. The compound is synthetic, a distinction that defines its chemical origin, and is utilized for its distinct relaxing effect on skeletal muscles in adults and adolescents, a focused therapeutic positioning.

Composition and Physical Form of Cyclobenzaprine Hydrochloride

The preparation is a single-ingredient product containing the active substance, Cyclobenzaprine Hydrochloride (C20H21N cdot HCl), which is chemically categorized as a tricyclic amine salt. It is formulated for oral administration and is supplied in various dosage forms, including the immediate-release tablet and the extended-release capsule. The availability of both release profiles allows for the selection of the form best suited for the patient’s need for acute or sustained systemic delivery of the compound.

General Purpose: What Does Fexmid Help to Relieve?

The primary therapeutic purpose of Fexmid is to provide relief from painful discomfort and stiffness associated with acute muscle spasms, such as those that might arise from sudden injury or strain. It functions by reducing the persistent, excessive nerve activity, known as tonic somatic motor activity, that contributes to muscular tension. The relaxation achieved through this central mechanism helps break the cycle of pain and tension, thereby serving as an adjunct to rest and physical therapy during short-term recovery, a typical use scenario supported by clinical guidelines.

Regulatory References

  1. DailyMed Label for Cyclobenzaprine

What side effects are possible with Fexmid?

The official safety documentation for Fexmid (Cyclobenzaprine Hydrochloride) is categorized by frequency of occurrence and the physiological systems affected, based strictly on government regulatory review. The most frequently documented adverse reactions, classified as Common in regulatory labeling, are related to the drug's effect on the central nervous system and its anticholinergic properties. These include Drowsiness, Dry Mouth, Fatigue, and Dizziness.

System-Organ-Class Groupings and Serious Reactions

Adverse reactions are grouped by System-Organ-Class, primarily listing Nervous System Disorders (such as somnolence and headache) and Gastrointestinal Disorders (including constipation and nausea). Serious adverse reactions explicitly highlighted in regulatory texts include severe Cardiac Disorders (e.g., Arrhythmias, Tachycardia) and the potential for Serotonin Syndrome when cyclobenzaprine is used alongside other serotonergic agents.

Safety Constraints and Special Populations

Specific regulatory constraints define limitations on use. The medicine is contraindicated in individuals with certain pre-existing conditions, including hyperthyroidism, specific cardiac conduction disturbances, and congestive heart failure. Official labeling also restricts use with MAO inhibitors (Monoamine Oxidase inhibitors) and advises that use is generally not recommended in older adults or in cases of moderate or severe hepatic impairment. The majority of adverse events are typically observed during the initial phase of treatment.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile indicates that Cyclobenzaprine overdose may manifest as Central Nervous System (CNS) effects, including drowsiness, confusion, tremor, agitation, slurred speech, or, in severe cases, coma and seizures. Overdose may also present with physiological effects such as tachycardia (rapid heartbeat) and hypertension.

Documented Severe Outcomes

Severity Classification Manifestations
Life-Threatening Cardiac arrest, severe hypotension, and cardiac dysrhythmias. Clinically significant ECG changes, such as QRS widening, are documented indicators of toxicity.
Syndromes The potential for Serotonin Syndrome and Neuroleptic Malignant Syndrome (NMS) is noted, particularly with co-ingestion of other serotonergic agents.

Mandated Emergency Action

Immediate medical attention is required for any suspected overdose. Contact a poison control center for guidance, as management is complex and supportive. If the person has collapsed, is experiencing a seizure, or cannot be awakened, emergency services must be called immediately.

The regulatory text specifies that no specific antidote is known; therefore, treatment is symptomatic and supportive. This includes the need for hospital monitoring and continuous cardiac observation due to the risk of delayed or rapidly developing severe cardiac events. Special consideration is given to the elderly and individuals with hepatic impairment, as these populations may face increased risk of adverse outcomes.

Therapeutic Uses of Fexmid

What Fexmid Treats: Main Uses and Benefits

Fexmid (Cyclobenzaprine) is commonly used to provide symptomatic support for a short duration, helping with the easing of painful and often disruptive symptoms associated with involuntary muscle contractions. It is applied as an adjunct to rest and physical therapy to help with the easing of muscle spasm, which is a key approach in managing acute musculoskeletal conditions.

It is relevant for easing symptoms related to localized muscle stiffness, rigidity, and tenderness that are associated with spasms. The primary clinical conditions where this assistance is used include muscle strains, sprains, and other localized events that result in acute muscle spasms.

“It is often used when symptoms intensify, providing supportive relief that may assist patients with better coping during phases of rehabilitation.”


Quick Fact: Relief for Acute Muscle Spasms

The medication contributes to improved day-to-day comfort during periods of heightened symptoms and may assist patients with maintaining a sense of stability when symptoms become more noticeable, thus contributing to easing the overall symptom load.

Eligibility and Restrictions for Use

Fexmid (Cyclobenzaprine) eligibility is strictly defined by regulatory documents based on patient age, health status, and concurrent medication use. The medicine is approved for use in adults and adolescents 15 years of age and older. Safety and effectiveness have not been established in children younger than 15 years. Furthermore, use of the extended-release formulation is not recommended for older adults aged 65 years and above.

Several conditions render the medicine contraindicated, meaning a patient must not use it. These absolute prohibitions include a known hypersensitivity to the drug, hyperthyroidism, or any use of a Monoamine Oxidase Inhibitor (MAOI) within the preceding 14 days. Cardiac contraindications also apply, specifically during the acute recovery phase of a myocardial infarction and for patients with severe heart issues, such as heart block, conduction disturbances, arrhythmias, or congestive heart failure.

Restrictions based on organ function also affect eligibility: Fexmid is not recommended for individuals with moderate to severe hepatic impairment. For pregnancy, use is considered only if clearly needed, as adequate human data are lacking. Caution is also advised during lactation due to unknown effects on the nursing infant.

What should I know about interactions with other medicines?

Fexmid Interactions with other medicines and products

Official regulatory documents define specific drug and substance interaction patterns for Cyclobenzaprine:

Interaction Classification Interacting Medicines or Substances Regulatory Constraint
Contraindicated Combination Monoamine Oxidase Inhibitors (MAOIs) Prohibited within 14 days of use or discontinuation.
Pharmacodynamic Risk Serotonergic Drugs (e.g., SSRIs, SNRIs, Tramadol) Reported risk of developing Serotonin Syndrome.
Additive Depression Central Nervous System (CNS) Depressants, Alcohol Effects may be enhanced, increasing CNS depression.
Pharmacodynamic Risk Anticholinergic Medications Potential for additive anticholinergic adverse effects.
Altered Drug Clearance Mild Hepatic Impairment, Elderly Patients (65+) Increased systemic exposure (AUC and Cmax) due to reduced clearance, raising susceptibility to interactions.
Exposure Modification Food (with Extended-Release Form) Statistically significant increase in C max (35%) and AUC (20%).

The regulatory profile strictly mandates that Cyclobenzaprine must not be administered concomitantly with MAOIs, nor within 14 days of discontinuing such agents, due to the potential for severe reactions. Additionally, official warnings highlight the risk of additive serotonergic and CNS depressant effects when co-administered with other agents in these categories. Special population notes confirm that reduced clearance in the elderly and individuals with mild hepatic impairment results in elevated systemic drug exposure. This structure confirms specific constraints and prohibitions based solely on documented risk.

Mechanism of Action

How Fexmid Works

Fexmid (cyclobenzaprine) acts centrally, exerting its primary influence within the central nervous system. Its main site of action is the brainstem, particularly the locus coeruleus. Fexmid functions as an antagonist at the serotonin type 2 (5- HT2) receptors, though it also exhibits affinity for alpha1-adrenergic receptors. The modulation of these monoaminergic systems affects descending neurotransmission to the spinal cord.

Activation of these descending pathways results in the reduction of excessive firing rates among gamma- and alpha-motoneurons, which are located in the ventral horn of the spinal cord. This action consequently decreases efferent motor impulses relayed to skeletal muscles. The mechanism is distinct from that of neuromuscular blocking agents, as Fexmid does not directly interfere with signaling at the neuromuscular junction. This systemic modification of motoneuron activity represents the core physiological consequence of Fexmid’s pharmacodynamics.

Dosage and Administration Information

How Fexmid is Used: Administration Guidelines

Fexmid (Cyclobenzaprine) is administered through the oral route only. It is available in two distinct oral forms: the Immediate-Release (IR) tablet and the Extended-Release (ER) capsule. The medicine is prescribed as an adjunct to rest and physical therapy during short-term management of acute musculoskeletal conditions.


Dosage and Frequency Patterns

The established usage pattern for Fexmid is defined by the release profile of the formulation:

  • IR Tablets: The standard initial dose for adults is 5 mg, taken three times per day (TID). This may be increased to 10 mg TID, with the maximum recommended dose totaling 60 mg daily.
  • ER Capsules: The standard regimen is 15 mg taken once daily. The maximum dose is 30 mg once daily.

Both forms may be administered with or without food. For the ER capsule, the medication must be swallowed whole. If necessary, the contents may be sprinkled onto a tablespoon of applesauce and swallowed immediately, but they must not be crushed or chewed.


Duration and Population Rules

Usage of Cyclobenzaprine is typically limited to short periods, no longer than two or three weeks. This time constraint is consistent with the generally brief nature of the acute spasms the medicine is intended to address.

Population-Specific Instructions:

  • Older Adults: Use of the IR tablet should be initiated with the lower 5 mg dose, with careful titration. The ER capsule is not recommended for this population.
  • Hepatic Impairment: Patients with mild impairment should start at 5 mg (IR) and titrate slowly. Use is not recommended in those with moderate or severe hepatic impairment.

If a dose is missed, it should be skipped if it is close to the time for the next scheduled dose; patients are instructed not to take two doses at the same time.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fexmid

Evidence for Use in Acute Muscle Spasm

Research has explored cyclobenzaprine relevant in research exploring symptoms during acute muscle spasms, such as those that may accompany strains or localized injuries. Cyclobenzaprine was studied for short-term symptom patterns in numerous randomized controlled trials (RCTs) that included comparison against an inactive placebo. These studies, primarily involving adult populations, monitored patient experiences related to outcomes related to physical discomfort, including local pain and muscle spasm severity, as well as patient-reported outcomes related to daily functioning or activity level. Findings describe patterns observed in these short-term trials.

What Research Was Conducted in Comparison to Other Treatments

Studies have also explored cyclobenzaprine in comparison to other pharmacological and non-pharmacological approaches. Researchers compared cyclobenzaprine against a placebo to determine the difference in how symptoms evolved in the observed populations. Research examined cyclobenzaprine in trials alongside other muscle relaxants; the evidence highlights that comparative evidence is lacking regarding consistent patterns across different treatments. Some studies explored combination approaches and reported patterns related to symptom change in those groups compared to groups using cyclobenzaprine alone.

Long-Term Data and Follow-up Duration in Research

The evidence base is primarily derived from research focusing on acute conditions, meaning the follow-up durations were limited—most key studies observed responses over defined time intervals of two to three weeks at most. Evidence derived from these settings has limited information for long-term outcomes, and research has not fully established the patterns of use or symptom changes beyond this short-term period.

Evidence in Specific Patient Groups and Populations

Data for certain groups remain insufficient. Research exploring effects in children and adolescents (under 15 years of age for the immediate-release tablet) is limited. Similarly, research examined cyclobenzaprine in older adults (65 years and older); the data show patterns related to how the substance is processed by the body, which was observed in some studies to differ from younger adult populations.

Research Gaps and What Remains Uncertain About Cyclobenzaprine

The research highlights what is known—and what is still uncertain. One key limitation is that cyclobenzaprine was not studied for or found to be relevant in addressing symptoms associated with muscle spasm caused by certain central nervous system diseases, such as spasticity. While cyclobenzaprine was evaluated in studies for its primary purpose, subgroup findings are uncertain for specific conditions and extended durations.

Frequently Asked Questions (FAQ)

Common questions about Fexmid (FAQ)


Q: How is Fexmid different from other general over-the-counter pain medicines?

Official documents state that Fexmid is classified as a prescription skeletal muscle relaxant. Unlike common over-the-counter pain relievers, Fexmid acts centrally within the brain and nervous system to help relax muscles. It is not considered a general pain reliever.


Q: What type of conditions cause the muscle spasms that Fexmid is intended for?

Fexmid is indicated for muscle spasms that occur with acute, painful musculoskeletal conditions. This includes spasms that may arise from sudden localized injuries, muscle strains, or general issues like low back or neck pain. Its use is limited to these acute conditions.


Q: Is it true that Fexmid is related to antidepressants?

Yes, regulatory documents describe Fexmid as being structurally related to the tricyclic antidepressant (TCA) class of medicines. Its mechanism of action also involves the modulation of monoaminergic systems, similar to TCAs.


Q: Is Fexmid considered a tricyclic antidepressant?

Although Fexmid is structurally related to tricyclic antidepressants, it is clinically classified as a prescription skeletal muscle relaxant. Its primary therapeutic use is strictly for relieving acute muscle spasms.


Q: Can Fexmid be used to improve sleep or insomnia?

Fexmid is indicated only as an adjunct to rest and physical therapy for treating muscle spasms. While drowsiness and fatigue are frequently reported side effects, the medicine is not officially indicated or approved for the treatment of sleep disorders or insomnia.


Q: How quickly can a person expect to feel the muscle relaxing effect of Fexmid?

According to official product information, the muscle relaxing effect of the immediate-release tablet may begin to be felt within 30 minutes to one hour after administration.


Q: How long does Fexmid stay in a person’s system after the last dose?

Official pharmacokinetic data shows that Fexmid is eliminated slowly from the body. The effective plasma half-life—the time it takes for half the drug to be eliminated—is reported to be about 18 hours, though this can range widely from 8 to 37 hours.


Q: What is the typical duration of Fexmid's effects after one tablet?

For the immediate-release tablet, the duration of action is typically 4 to 6 hours. This is different from the extended-release capsule, which is designed to be taken less frequently.


Q: Do the extended-release and immediate-release forms of Fexmid work differently in terms of duration?

Yes, the two formulations have different intended durations of effect. The immediate-release tablet is typically prescribed for administration three times daily. The extended-release capsule is designed to provide sustained action and is typically prescribed to be taken once daily.


Q: How long does the drowsiness from Fexmid usually last?

Regulatory information does not specify the exact duration of drowsiness for an individual dose. However, Fexmid has a relatively long half-life (around 18 hours), meaning its sedative effects on the central nervous system may persist for an extended period.


Q: Can Fexmid cause an increase in heart rate or irregular heartbeat?

Yes, an increased heart rate or tachycardia is reported as a less frequent side effect. Regulatory safety documents also mention that severe cardiac rhythm abnormalities are a serious potential adverse reaction.


Q: Is it possible to experience confusion or hallucinations while taking Fexmid?

Official adverse reaction documents list confusion as a less common reaction. There have also been reports of transient visual hallucinations occurring, especially when high doses or an overdose is involved.


Q: Does Fexmid have any known long-term side effects?

Fexmid is only recommended for use for a short duration, typically no longer than two or three weeks. This is because adequate research evidence for its effectiveness and safety beyond this short period is not available in official regulatory data.


Q: Does Fexmid interact with anti-anxiety medications (like benzodiazepines)?

Yes, combining Fexmid with anti-anxiety medications, such as benzodiazepines, can lead to additive nervous system depression. This increases the likelihood and intensity of side effects like dizziness, drowsiness, confusion, and difficulty concentrating.


Q: Is it safe to take Fexmid with over-the-counter pain relievers such as ibuprofen or acetaminophen?

Certain drug interaction checks have not shown an interaction between Fexmid and over-the-counter pain relievers like ibuprofen or acetaminophen. However, regulatory guidance emphasizes the importance of consulting a healthcare provider before combining any prescription and non-prescription medicines.


Q: Can Fexmid interact with herbal supplements like St. John's Wort?

Although not explicitly listed in the product label, Fexmid's structural relation to antidepressants means official warnings highlight the risk of developing Serotonin Syndrome when combined with other serotonergic agents, which may include St. John's Wort.


Q: Does caffeine affect how Fexmid works?

No direct interaction between Fexmid and caffeine is generally reported in drug checks. However, regulatory guidance emphasizes that it is important to discuss all food and stimulant consumption with a healthcare professional when taking CNS depressants.


Q: Is there an interaction between Fexmid and certain cold or allergy medicines?

Yes, Fexmid has properties described as having an atropine-like action. Due to this property, the official product information notes that using Fexmid with anticholinergic medications may increase the risk of adverse anticholinergic effects.


Q: Can Fexmid be taken with muscle relaxers that work differently, like tizanidine?

Combining Fexmid with other muscle relaxants is generally approached with caution because both are central nervous system (CNS) depressants. This combination carries the risk of additive effects, significantly increasing sedation, drowsiness, and cognitive impairment.


Q: Is Fexmid appropriate for muscle spasms resulting from cerebral palsy or spinal cord disease?

Regulatory documents explicitly state that Fexmid has not been found effective for treating the spasticity that is associated with neurologic conditions. This includes spasms linked to conditions such as cerebral palsy.


Q: Are there warnings about using Fexmid for people with glaucoma or eye pressure issues?

Yes, official warnings exist due to the drug's atropine-like action. Due to this property, the drug's official warnings highlight the need for caution for individuals with a history of angle-closure glaucoma or increased intraocular pressure (pressure inside the eye).


Q: Does Fexmid affect a person's ability to drive or operate machinery?

Official safety information notes that due to the potential for dizziness and drowsiness, activities requiring full mental alertness, such as driving or operating hazardous machinery, should be avoided until an individual knows how the medicine affects them.


Q: Is Fexmid considered a habit-forming medicine?

No, Fexmid is not classified as a controlled substance by the US Drug Enforcement Administration (DEA). Unlike certain other medications, it does not possess physical addictive properties or a similar abuse potential.


Q: What is the evidence for Fexmid being used to help with fibromyalgia?

Official documents indicate the drug is only approved for muscle spasms. While some studies have explored its use for fibromyalgia, data supporting its routine use for this condition is limited.


Q: Do different strengths (5mg, 7.5mg, 10mg) of Fexmid affect the likelihood of side effects?

Studies have explored the relation between dose and side effects. Some evidence indicates that using a lower dose (such as 5 mg) may be associated with a lower likelihood of sedation compared to using the higher 10 mg dose.


Q: What should a person know about withdrawing or stopping Fexmid after short-term use?

Official safety information notes that abruptly stopping the medicine after prolonged use may result in withdrawal symptoms. These symptoms can include headache, nausea, general malaise, and fatigue. Regulatory information notes that if discontinuation is necessary after prolonged use, it may need to be done gradually to minimize the risk of withdrawal symptoms.


Q: Are there specific instructions for administering the extended-release form of Fexmid if one cannot swallow pills?

Yes, the official administration guidelines describe an alternative method for the extended-release capsule. If the capsule cannot be swallowed whole, its contents may be sprinkled onto a tablespoon of applesauce and swallowed immediately. It is strictly noted that the capsules must not be crushed or chewed.


Q: Is Fexmid ever prescribed for purposes other than muscle spasms?

The FDA-approved indication for Fexmid is limited to muscle spasm associated with acute, painful musculoskeletal conditions. Official documents do not address or confirm its use for other purposes.


Q: Are certain populations more likely to experience drowsiness from Fexmid?

Yes, the elderly population is noted in official documentation as being more susceptible to side effects. Use in older adults is generally not recommended due to the potential for more severe central nervous system effects, including confusion and delirium, which are linked to its sedative properties.


Q: Why do some sources state Fexmid should be used along with rest and physical therapy?

Fexmid is indicated as an adjunct—a medicine used in addition to other treatments—along with rest and physical therapy. This is because the drug's purpose is to manage the muscle spasm symptom that accompanies the underlying acute musculoskeletal condition.

How should Fexmid be stored and disposed of?

How to Store and Dispose of Fexmid?

The official storage and disposal guidelines for Fexmid (cyclobenzaprine hydrochloride) are mandated by regulatory agencies to ensure the medicine remains stable and is discarded safely.

Official Storage Requirements

The tablets must be stored at Controlled Room Temperature, which is between 20^circ and 25 C (68^circ to 77 F). Storage must be away from excess moisture and heat, and the product should not be frozen. It must be kept in a tight, light-resistant container.

Child-Safety and Discard Rules

It is mandatory to keep Fexmid out of the reach of children. For disposal, the preferred method is an authorized drug take-back program. The medicine must not be flushed down the toilet. If take-back is unavailable, unused or expired tablets should be mixed with an unappealing substance, such as dirt or used coffee grounds, sealed in a bag, and then placed in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fexmid found in:

A-Z Index: